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Introduction: Cellular senescence is a terminal cell proliferation arrest that can be triggered by oncogenes. One of
the traits of oncogene-induced senescence (OIS) is the so-called senescence-associated secretory phenotype or
senescence secretome. Depending on the context, the non-cell autonomous effects of OIS may vary from tumor
suppression to promotion of metastasis. Despite being such a physiological and pathologically relevant effector, the
mechanisms of generation of the senescence secretome are largely unknown.
Methods: We analyzed by label-free proteomics the secretome of p95HER2-induced senescent cells and compared
the levels of the membrane-anchored proteins with their transcript levels. Then, protein and RNA levels of ADAM17
were evaluated by using Western blot and reverse transcription-polymerase chain reaction, its localization by using
biotin labeling and immunofluorescence, and its activity by using alkaline phosphatase-tagged substrates. The
p95HER2-expressing cell lines, senescent MCF7 and proliferating MCF10A, were analyzed to study ADAM17
regulation. Finally, we knocked down ADAM17 to determine its contribution to the senescence-associated
secretome. The effect of this secretome was evaluated in migration assays in vitro and in nude mice by assessing
the metastatic ability of orthotopically co-injected non-senescent cells.
Results: Using breast cancer cells expressing p95HER2, a constitutively active fragment of the proto-oncogene
HER2 that induces OIS, we show that the extracellular domains of a variety of membrane-bound proteins form part
of the senescence secretome. We determine that these proteins are regulated transcriptionally and, in addition, that
their shedding is limited by the protease ADAM17. The activity of the sheddase is constrained, at least in part, by
the accumulation of cellular cholesterol. The blockade of ADAM17 abrogates several prometastatic effects of the
p95HER2-induced senescence secretome, both in vitro and in vivo.
Conclusions: Considering these findings, we conclude that ectodomain shedding is tightly regulated in oncogene-
induced senescent cells by integrating transcription of the shedding substrates with limiting ADAM17 activity. The
remaining activity of ADAM17 contributes to the non-cell autonomous protumorigenic effects of p95HER2-induced
senescent cells. Because ADAM17 is druggable, these results represent an approximation to the pharmacological
regulation of the senescence secretome.Introduction
Cellular senescence is a terminal cell proliferation arrest
characterized by a distinct phenotype. Compared with
their proliferating counterparts, senescent cells have
enlarged volumes, display a flattened and vacuolated
morphology, and express a variety of markers. The most* Correspondence: jarribas@vhio.net
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Cellular senescence can be triggered by a variety of
stressors, including oncogenes, resulting in what is
known as oncogene-induced senescence (OIS) [1]. For
example, expression of p95HER2, an oncogenic fragment
of the tyrosine kinase receptor HER2, induces OIS in a
variety of cell lines [2].
The onset of senescence is characterized by a pro-
found change in the secretome (i.e., all factors secreted
by a given cell) that results in the so-called senescence-
associated secretory phenotype or senescence secretomearticle is distributed under the terms of the Creative Commons
creativecommons.org/licenses/by/4.0), which permits unrestricted use,
um, provided you give appropriate credit to the original author(s) and the
ons license, and indicate if changes were made. The Creative Commons
eativecommons.org/publicdomain/zero/1.0/) applies to the data made
ted.
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has disparate effects. It may promote [3] or impair [4]
immune surveillance against tumor cells in the liver and
in the prostate, respectively. In fact, senescent cells may
be short-lived or long-lived in vivo, in both immuno-
competent [3–5] and immunosuppressed [2, 6] mice.
Furthermore, the senescence secretome can suppress [7]
or promote [8] tumor growth. These results can be ra-
tionalized assuming that the potent tumor suppressive
effects of senescence can be reversed, particularly in ad-
vanced tumors, by modifying the composition of the
senescence secretome and, thus, its effects on target
cells.
Because the non-cell autonomous effects of senescent
cells can suppress or contribute to tumor progression,
the up- or downregulation of the senescence secretome
could be a therapeutic strategy to treat cancer and per-
haps many other diseases related to cellular senescence
[1]. Unfortunately, to date, there are no known strategies
to regulate the production of the senescence secretome.
The proteolytic release of the extracellular domain of
transmembrane proteins is known as ectodomain shed-
ding. This type of limited proteolysis affects a diverse
group of functionally unrelated transmembrane proteins,
including membrane-anchored growth factors, cytokines,
cell adhesion molecules, or transmembrane proteases
[9–12]. The proteases that cleave the vast majority of
these transmembrane proteins are the metalloprotease
disintegrins ADAM17 (also known as tumor necrosis
factor-alpha-converting enzyme) or ADAM10 or both
(reviewed in [13]).
Some components frequently secreted by senescent
cells, such as transmembrane epidermal growth factor
(EGF)-like growth factors, are generated through ectodo-
main shedding. However, the contribution of ectodomain
shedding to the senescence secretome remains largely un-
explored. Although ADAM17 has been recently shown to
be active in senescent cells [14], its regulation or func-
tional importance during senescence is unknown.
Here, we show that approximately 10 % of the compo-
nents of the secretome of p95HER2-induced senescent
cells are generated through the shedding of the ectodo-
mains of membrane-anchored proteins. The main mech-
anism regulating the release of these ectodomains is the
transcriptional regulation of the membrane-anchored
precursors. Functional analysis shows that ADAM17
plays a major role in these cleavages. However, although
ADAM17 protein levels increase during p95HER2-
induced OIS, the activity of the metalloprotease does
not increase, and this is likely because of the accumula-
tion of cholesterol, a negative regulator of ADAM17, in
senescent cells. Finally, we show that ADAM17 activity
is required for several non-cell autonomous protumori-
genic and prometastatic effects of p95HER2-inducedsenescent cells. Because the activity of ADAM17 can be
pharmacologically downregulated, these results indicate
that inhibition of this metalloprotease could be a means




Doxycycline (Doxy.), phorbol myristate acetate, biotin, 1-
10-phenanthroline, methyl-beta-cyclodextrin (MβCD), in-
sulin, EGF, and hydrocortisone were from Sigma-Aldrich
(St. Louis, MO, USA). Batimastat (BB94) was from Merck
(Schwalbach, Germany).
Antibodies
Rabbit anti-phospho ERK (T202/Y204; #4370), anti-ERK
(#9102), anti-phospho Akt (S473; #9271), anti-Akt (#9272),
anti-phospho EGF receptor (EGFR) (Y1068; #3777), and
anti-EGFR (#4267) were from Cell Signaling Technology
(Danvers, MA, USA). Mouse anti-EpCAM (#sc-25308)
was from Santa Cruz Biotechnologies (Santa Cruz, CA,
USA), and mouse anti-pan actin (#MA5-11869) was from
Thermo Scientific (Lafayette, CO, USA). Mouse anti-APP
(#MAB348) and rabbit anti-ADAM17 (#AB19027) were
from Millipore (Billerica, MA, USA). Rabbit anti-ADAM17
(#ab39162), rabbit anti-ADAM10 (#ab1997), goat anti-
Met receptor (#ab10728), and mouse anti-glucose-6-phos-
phate (GPI) (#ab66340) antibodies were from Abcam
(Cambridge, MA, USA). Rabbit anti-DDR1 (#10730) was
from Sino Biological Inc. (Beijing, PR China), rabbit anti-
GAPDH (#2275-PC-1) was from Trevigen (Gaithersburg,
MD, USA), and mouse anti-HER2 (#MU-134-UC) was
from BioGenex (San Ramon, CA, USA). Mouse anti-
EphB4 (#AF446) was from R&D Systems (Minneapolis,
MN, USA). Fluorochrome-conjugated antibodies were
from Molecular Probes (Life Technologies, Grand Island,
NY, USA).
Transcriptomic and proteomic analyses
Transcripts and secretome analysis were performed as
described in [15] and [2], respectively. GeneChip expres-
sion probe array Gene Expression Omnibus reference
number is GSE68256. Heatmap hierarchical clustering
was performed as in [16].
Plasmids
The expression vectors encoding alkaline phosphatase
(AP)-tagged amphiregulin (AP-Areg), transforming growth
factor-alpha (AP-TGF-α), and betacellulin (AP-BTC) were
a kind gift from Shigeki Higashiyama (Department of
Biochemistry and Molecular Genetics, Ehime University
Graduate School of Medicine, Japan). Subcloning in the
lentiviral vector pLex (Thermo Scientific) was performed by
conventional molecular biology techniques. pGIPZ-based
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control were from Thermo Scientific. p95HER2 in
pENTR1Dual (Invitrogen, Paisley, UK) was transferred
into pINDUCER20 using LR Clonase II (Invitrogen). For
control pINDUCER20 (pINDUCER20-Empty), cloram-
phenicol and ccdB genes were removed from pENTR1A
Dual (5-SalI and 3’-XhoI) and the minimal MCS was
transferred to pINDUCER20. pINDUCER20 was kindly
provided by Stephen J Elledge (Howard Hughes Medical
Institute, Chevy Chase, MD, USA) [17].
Cell culture and infections
MCF7, MCF7 Tet-Off p95HER2, and MDA-MB-231-Luc
were maintained as previously described [2]. MCF10A
was maintained in Dulbecco’s modified Eagle’s medium,/
F-12, 10 % fetal bovine serum (FBS), 4 mmol/l L-
glutamine (all from Gibco, Carlsbad, CA, USA), 9 μg/ml
insulin, 0.5 μg/ml hydrocortisone, and 18 ng/ml EGF.
MCF7 Tet-Off p95HER2 AP-Areg, AP-TGF-α, AP-BTC,
shControl, and shADAM17 were generated by infecting
MCF7 Tet-Off p95HER2 with the lentiviral particles ob-
tained transfecting HEK293T cells with the plasmids
described above (calcium phosphate method). Viral super-
natant was applied to the cells in the presence of 8 μg/ml
polybrene, and stable clones were selected with 1 μg/ml
puromycin. MCF10A was infected with pINDUCER20-
p95HER2 by using the same protocol, and selection was
performed with 200 μg/mL G418. MCF10A infection with
lentiviral vectors expressing AP-Areg and AP-TGF-α was
performed with the plasmids and method indicated above.
Protein extraction and immunoblotting
Cells were lysed in 20 mM Tris-HCl pH 7.4, 137 mM
NaCl, 2 mM EDTA pH 8.0, 10 % glycerol, 1 % NP-40, pro-
tease inhibitor cocktail (Roche, Penzberg, Germany), 1.3
mM sodium orthovanadate, 10 mM 1-10-phenanthroline,
and 1 μM BB94. Cell lysates were quantified by using the
Pierce BCA Protein Assay kit (Pierce, Rockford, IL, USA),
and equal amounts of protein were separated on SDS-
polyacrylamide gels and transferred onto nitrocellulose
membranes. These were blocked with 5 % bovine serum
albumin or skim milk in TBS-Tween 0.1 % and then incu-
bated with primary antibodies, and bound antibodies were
detected with the appropriate peroxidase-conjugated sec-
ondary antibodies (Amersham GE Healthcare, Piscataway,
NJ, USA) by using the ECL detection system (Millipore).
To detect ADAM17, the same amount of protein from
cell lysates was concentrated with wheat germ agglutinin
(WGA)-agarose beads (Vector Laboratories, Peterbor-
ough, UK) for 2 h at 4 °C. Proteins were eluted directly in
SDS-polyacrylamide gel electrophoresis loading buffer.
Determination of proteins in the collected conditioned
media was performed following the same protocol after
concentrating 100× the samples by using centricons(Amicon Ultracel 3K; Millipore). Densitometric quantifi-
cation was performed by using ImageJ software.
Enzyme-linked immunosorbent assay
Cells were plated and the next day were washed twice
with 1X phosphate-buffered saline (PBS), and medium
was changed to serum-free medium with L-glutamine.
Conditioned media were collected 48 h later, spun down
at 200×g for 5 min, and transferred to clean tubes.
Amphiregulin was determined in accordance with the
instructions of the manufacturer (RayBiotech, Norcross,
GA, USA).
mRNA expression
RNA was isolated by using an RNeasy Mini kit (Qiagen,
Hilden, Germany) and reverse-transcribed by using a
High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Weiterstadt, Germany) in accordance with
the instructions of the manufacturers. Quantitative re-
verse transcription-polymerase chain reaction was per-
formed by using Taqman primers (Applied Biosystems)
for ADAM17 (Hs01041915_m1), ADAM10 (Hs00153853_
m1), and GAPDH (Hs03929097_g1).
Biotin labeling
Cells were washed three times with ice-cold 1X PBS pH
8.0 and labeled with 1 mg/ml sulfo-NHS-LC-biotin
(Pierce) in 1X PBS pH 8.0 gently shaking for 1 h at 4 °C.
Biotin was inactivated by washing with 50 mM Tris pH
7.4, and cells were extensively washed with 1X PBS.
Then cells were harvested and lysed, and immunopre-
cipitation was performed by using an anti-ADAM17
antibody or a control IgG. Immunoprecipitates were
analyzed by Western blotting by using streptavidin-POD
conjugate (Roche) or anti-ADAM17 antibody (Abcam).
Confocal microscopy
Cells were seeded on glass coverslips, washed with 1X
PBS, fixed with 4 % formaldehyde for 20 min, and perme-
abilized with 0.2 % Triton X-100 for 10 min. 1X PBS con-
taining 1 % bovine serum albumin, 0.1 % saponin, and
0.02 % NaN3 was used for blocking (1 h), primary antibody
binding (2 h), and secondary fluorochrome-conjugated
antibody binding (40 min in dark). Preparations were
mounted by using Vectashield with DAPI (4’,6’-diamidino-
2-phenylindole) (Vector Laboratories). All procedures
were performed at room temperature. Images were cap-
tured by using an Olympus FV1000 confocal microscope
(Olympus Corporation, Tokyo, Japan).
Ectodomain shedding assay
MCF7 Tet-Off p95HER2 cells were induced for 5 days
and replated at the same cell concentration. Next day,
cells were washed with Opti-MEM (Invitrogen) without
Morancho et al. Breast Cancer Research  (2015) 17:106 Page 4 of 13serum or growth factors, and the medium was replaced
1 h later with fresh Opti-MEM with or without the indi-
cated stimuli. Cells and supernatants were harvested at
the designated time points, and AP activity was measured
at an absorbance of 405 nm after incubation with the AP
substrate 4-nitrophenyl phosphate (Sigma-Aldrich). At
least three wells per condition were performed, and the
ratio between the AP activity in the supernatant and the
cell lysate plus supernatant was calculated. The fold in-
crease in the ratio of AP activity relative to the control is
shown.
Proliferation assays
Proliferation was analyzed by cell counting. After trypsi-
nization, viable cells determined by trypan blue dye ex-
clusion were counted on a Neubauer chamber.
Senescence-associated β-galactosidase activity
Cells were plated on coverslips and analyzed by using a
senescence β-galactosidase staining kit (Cell Signaling
Technology) in accordance with the indications of the
manufacturer.
Filipin staining
Cells were washed three times with 1X PBS and fixed
with 3 % paraformaldehyde for 1 h at room temperature.
Washes were repeated, and cells were incubated with 1.5
mg/ml glycine in 1X PBS for 10 minutes. Staining was
performed for 2 h with 0.05 mg/ml filipin complex
(Sigma-Aldrich) in 1X PBS/10 % FBS. After the cells
were rinsed three times with 1X PBS, they were analyzed
by fluorescence microscopy (BX61 Olympus).
Migration assays
Cell migration was determined with 24-well format
Boyden chambers containing FluoroBlok PET mem-
branes with 8-μm pores (BD Biosciences, Heidelberg,
Germany). Conditioned media were obtained after incu-
bating cells with serum-free medium with glutamine for
48 h, spun down, and concentrated 100 times by using
centricons (Amicon Ultracel 3K). Concentrated condi-
tioned media were diluted 10 times in serum-free medium
and added to the bottom part of the Boyden chambers.
MDA-MB-231 Luc or MCF7 cells were plated in the
upper chambers and migration ability was evaluated 24 or
48 h later, respectively, by staining the cells with 1 μM
SYTO-9 (Life Technologies) and counting them on the
underside of the filters by using fluorescence microscopy.
Mouse model of breast cancer metastasis
MCF7 Tet-Off p95HER2 cells expressing a short hairpin
control or targeting ADAM17 were co-injected with
MDA-MB-231 Luc cells into the right flanks of 6- to 8-
week-old female BALB/c athymic mice (Charles RiverLaboratories, Paris, France) in addition to a 17β-estradiol
pellet (Innovative Research of America, Sarasota, FL,
USA). The expression of p95HER2 was repressed by add-
ing doxycycline (50 mg/kg per day) to the drinking water
until tumors were about 100 mm3. Tumor xenografts
were measured with calipers every 3 days, and tumor vol-
ume was determined by using the formula: (length ×
width2) × (pi/6). Tumors were resected when they reached
300 mm3, and metastatic colonization was monitored by
in vivo bioluminescence imaging with the IVIS-200 im-
aging system (PerkinElmer, Waltham, MA, USA). At the
end of the experiment, animals were anesthetized with a
1.5 % isofluorane-air mixture and were sacrificed by cer-
vical dislocation. Mice were maintained and treated in ac-
cordance with institutional guidelines of Vall d’Hebron
University Hospital Care and Use Committee.
Statistics
Data are presented as average ± standard deviation and
were analyzed by the two-sided Student t test. Results
were considered to be statistically significant at P value
of less than 0.05. All statistical analyses were conducted
by using the GraphPad Prism 5 Statistical Software
(GraphPad Software, Inc., La Jolla, CA, USA).
Results
Shedding of transmembrane molecules during
p95HER2-induced senescence
Expression of p95HER2 in different breast cancer cell
lines leads to OIS ([2] and Additional file 1: Figure. S1a).
Analysis of the media conditioned by control cells or
p95HER2-induced senescent cells by quantitative label-
free proteomics confirmed the profound change in the
secretome composition characteristic of OIS (Additional
file 1: Figure. S1b).
The analysis of the extracellular proteins identified
showed that the majority (79 %) contained neither signal
peptide nor transmembrane domain (Additional file 1:
Fig. S1c and Additional file 2: Table S1, Additional file 3:
Table S2 and Additional file 4: Table S3), indicating
that they are secreted through exosomes or unknown
secretory mechanisms; 10 % corresponded to proteins
that contained a signal peptide but not a transmembrane
or GPI domains (Additional file 1: Figure. S1c and
Additional file 4: Table S3), indicating that they are
released to the extracellular media through the canonical
secretory pathway. Finally, 11 % of the proteins were pre-
dicted to be membrane-anchored (Additional file 1: Figure.
S1c and Additional file 4: Table S3), opening the possibil-
ity that they are secreted through ectodomain shedding.
Confirming this possibility, sequence alignment showed
that virtually all the peptides identified by mass spectrom-
etry from selected transmembrane proteins corresponded
to extracellular domains (Additional file 5: Figure. S2). We
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membrane proteins, they have long intracellular domains;
identification of peptides corresponding to the intracellu-
lar domains would indicate that they are released through
exosomes or other mechanisms. We concluded that ap-
proximately 10 % of the components of the p95HER2-
induced senescence secretome are generated through
ectodomain shedding.
Regulation of the sheddome of p95HER2-induced
senescent cells
Proteomic analysis of membrane-anchored proteins
showed the profound change in the sheddome (i.e., the
part of the secretome generated by ectodomain shedding)
produced by p95HER2-induced senescent cells (Fig. 1a,
Proteins).Fig. 1 Protein ectodomain shedding during p95HER2-induced senescence. a L
as indicated in two independent experiments (#1 and #2). The extracellular me
(Additional file 1: Figure. S1). The heatmap shows log2FC of the normalized lev
treated as in left panel (a). b MCF7 Tet-Off p95HER2 cells were treated with or
and cell lysates were analyzed by Western blotting as indicated. c Quantitative
were expressed as average ± standard deviation. Note that the levels of Areg w
ectodomain levels and the log2FC of their corresponding transcripts levels, det
shown (R2 = 0.528); P <0.001 using the Spearman correlation coefficient. APP am
molecule, Ephrin type-B receptor 4, DDR1 discoidin domain receptor family, meAnalysis by Western blot of several randomly chosen
proteins confirmed the expected full-length species and
shed ectodomains in cell lysates and conditioned media,
respectively (Fig. 1b and Additional file 6: Table S4).
Confirming the proteomic analysis, compared with con-
trol proliferating cells, the levels of the soluble extracel-
lular domains of the tyrosine kinase receptor Met or the
EGF-like growth factor Areg increased during p95HER2-
induced senescence. In contrast, the extracellular do-
mains of the amyloid precursor protein (APP), the cell
adhesion molecule EpCAM, or the tyrosine kinase re-
ceptors DDR1 and EphB4 decreased (Fig. 1b, c).
The increased levels of the soluble ectodomains of Met
and Areg were concomitant with increased levels of the
cell-associated full-length proteins (Fig. 1b, c). Conversely,
the decrease in the levels of the soluble ectodomains ofeft, MCF7 Tet-Off p95HER2 cells were treated with or without doxycycline
dia were analyzed by label-free quantitative proteomics in triplicate (A-C)
els of soluble ectodomains. Right, transcriptomic analysis of the same cells
without doxycycline for 7 days. Conditioned media from the last two days
results from at least three independent experiments performed as in (b)
ere determined by enzyme-linked immunosorbent assay. d log2FC of the
ermined as described in (a), are represented. Linear regression line is
yloid precursor protein, Areg amphiregulin, EpCAM epithelial cell adhesion
mber 1, GAPDH glyceraldehyde 3-phosphate dehydrogenase
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length cell-associated counterparts. In the case of APP, the
levels of the transmembrane protein did not change; how-
ever, the levels of shedding decreased (Fig. 1b, c), indicat-
ing that, in senescent cells, this substrate is less accessible
to the metalloproteases that cleave its ectodomain or, al-
ternatively, that these metalloproteases are inhibited.
The transcriptomic analysis of the factors detected
though proteomics showed a direct correlation between
the levels of shed ectodomains and those of their corre-
sponding mRNAs (Fig. 1a, Transcripts and Fig. 1d). We
concluded that, during OIS, ectodomain shedding is reg-
ulated largely through the transcriptional control of
shedding substrates.Fig. 2 ADAM17 levels during oncogene-induced senescence. a MCF7 Tet-Of
and harvested at the specified time points. Then cells were lysed and cell lysa
densitometric quantification of the pro- and mature forms of ADAM17 and A
as average ± standard deviation. *P <0.05, **P <0.01 using the Student’s t test
reverse transcription-polymerase chain reaction in the same cells as in (a). Dat
three independent experiments are represented. Differences are not significan
presence or absence of doxycycline for 7 days and incubated with phosphate
described in the Methods section. Then cells were lysed and cell lysates were
analyzed by Western blotting by using streptavidin-peroxidase (Str.) or anti-AD
experiments is expressed as average ± standard deviation. **P <0.01 using th
(green) and DAPI (4’,6’-diamidino-2-phenylindole) counterstaining (nuclei, red)
Bottom and left panels in each image represent Z-stack integration in the X an
cultured for 7 days without or with doxycycline. Then senescence-associated
shown. f The same cells as in (e) were lysed and cell lysates were analyzed byADAM17 expression in p95HER2-induced senescent cells
ADAM17 cleaves Areg [18], APP [19], DDR1 [20], EphB4
[21], Met [22], and EpCAM [23]. Therefore, we analyzed
the levels of ADAM17 during the onset of p95HER2-
induced senescence.
Expression of p95HER2 during 2 days results in the ir-
reversible onset of senescence, and after 5–7 days the
cells display the full senescence phenotype [2]. Concomi-
tantly, the levels of total ADAM17 increased (Fig. 2a,
bottom panels). ADAM17 is synthesized as a zymogen
(proADAM17), which contains a pro-domain that in-
hibits the metalloprotease active site. During transport
through the trans-Golgi network, furin-like pro-protein
convertases remove the pro-domain generating maturef p95HER2 cells were cultured in the presence or absence of doxycycline
tes were analyzed by Western blotting with the indicated antibodies. The
DAM10 was performed in four independent experiments and is expressed
. b Relative ADAM17 and ADAM10 mRNA expression was determined by
a were normalized to 18S mRNA. Averages and standard deviations of
t statistically (ns). c MCF7 Tet-Off p95HER2 cells were cultured in the
-buffered saline (unlabeled) or sulfo-NHS-LC-biotin (biotinylated) as
incubated with anti-ADAM17 antibody and immunoprecipitates were
AM17 (αA17). The densitometric quantification of six independent
e Student’s t test. d Representative immunofluorescence of ADAM17
in MCF7 Tet-Off p95HER2 cells cultured with or without doxycycline.
d Y dimensions, respectively. e MCF10A Tet-On p95HER2 cells were
β-galactosidase was performed. Representative bright-field images are
Western blot with the indicated antibodies. Doxy doxycycline
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loprotease (Fig. 2a, bottom panels) is largely post-
transcriptional (Fig. 2b). Analysis of its subcellular
distribution by means of biotinylation of intact cells and
immunofluorescence showed that ADAM17 is predomin-
antly intracellular in proliferating cells and that it accumu-
lates at the cell surface in p95HER2-induced senescent
cells (Fig. 2c, d). ADAM10 also participates in ectodomain
shedding, and some of the substrates of ADAM17, such
as APP, are also cleaved by ADAM10 [13]. However,
ADAM10 protein was not upregulated during p95HER2-
induced senescent cells; in fact, relative to control cells,
p95HER2-induced senescent cells showed a slight but re-
producible downmodulation of ADAM10 which could
not be explained by a reduction in its cognate transcript
(Fig. 2a, b).
To determine whether the upregulation of ADAM17
is the result of the activity of p95HER2 independently of
the senescence status, we analyzed MCF10A cells. Ra-
ther than inducing OIS (Fig. 2e), expression of p95HER2
in this immortalized non-transformed mammary epithe-
lium cell line, accelerates proliferation [2]. The levels of
ADAM17 remained unchanged in MCF10A expressing
p95HER2 (Fig. 2f ), indicating that overexpression of the
metalloprotease is likely linked to OIS rather than to the
mere expression of the constitutively active fragment of
HER2. We concluded that the levels of ADAM17 are up-
regulated during p95HER2-induced cellular senescence.
Role of ADAM17 in the shedding of different components
of the senescence secretome
To determine whether ADAM17 plays a role in the shed-
ding of transmembrane proteins during OIS, we knocked
it down from the MCF7 Tet-Off p95HER2 cells. We used
two independent shRNAs targeting ADAM17 to generate
two cell lines (Fig. 3a). Although we observed similar re-
sults with both cell lines, for simplicity, except in Fig. 3d,
we show the results obtained with only one of them. The
downmodulation of the protease did not affect the morph-
ology or the levels of SAβG in p95HER2-induced senes-
cent cells (Fig. 3b). The proliferation of control cells or the
inhibition of proliferation induced by p95HER2 expression
was also unaffected (Fig. 3c).
In a proteomic analysis of the media conditioned by
p95HER2-induced senescent cells expressing control
shRNAs or the shRNAs targeting ADAM17, we quanti-
fied the soluble ectodomains of 68 % (46 out of 68) of
the membrane-anchored proteins shown in Fig. 1b. The
levels of 37 % of these ectodomains (17 out of 46) de-
creased in the media conditioned by the ADAM17
knockdown cell lines (Fig. 3d and Additional file 7:
Table S5), showing that the metalloprotease participates
in the cleavage of the corresponding membrane-anchored
factors.To validate these results, we showed that, in p95HER2-
induced senescent cells, the knockdown of ADAM17 re-
sulted in an approximately 80 % reduction of the shedding
of Areg and Met (Fig. 3d, e and f).
In agreement with the results shown in Fig. 1c, com-
pared with that in control proliferating cells, the shedding
of APP was reduced in p95HER2-induced senescent cells
(Fig. 3g). Confirming the result of the proteomic analysis
(Fig. 3d), in ADAM17 knockdown senescent cells, the
shedding of APP was further reduced (Fig. 3g).
Collectively, these results show that ADAM17 contrib-
utes to protein ectodomain shedding during OIS. We esti-
mate that this metalloprotease contributes to the cleavage
of approximately one third of the membrane-anchored
proteins that undergo ectodomain shedding during OIS.
ADAM17 activity in p95HER2-induced senescent cells
Although the results in Fig. 3 clearly show a role of
ADAM17 in the generation of the senescence secretome,
the inhibition of the shedding of APP during p95HER2-
induced senescence (Figs. 1b, c and 3g), despite the in-
crease of ADAM17 levels (Fig. 2a), indicates that the
activity of the metalloprotease may be partially inhibited
in p95HER2-induced senescent cells.
Previous reports have shown that ADAM17 is inhib-
ited by high cholesterol levels [25–30]. Senescent cells
tend to accumulate cholesterol [31]; in fact, it has been
previously shown that HER2 (NeuT)-induced senes-
cence results in a marked accumulation of cellular
cholesterol [32]. Thus, we reasoned that the high levels
of cholesterol in p95HER2-induced senescent cells may
lead to the accumulation of partially inactive ADAM17.
As expected, treatment with MβCD, a compound
that selectively extracts membrane cholesterol, re-
duced the levels of cholesterol in p95HER2-senescent
cells (Fig. 4a).
MβCD did not affect the expression of p95HER2 or its
signaling ability (Fig. 4b); however, it completely pre-
vented the increase in ADAM17 protein levels that oc-
curs during OIS. In contrast, the levels of ADAM10
were largely unaffected by the same treatment (Fig. 4b,
bottom panels).
We directly monitored the effect of cholesterol depletion
on the activity of ADAM17 using vectors encoding the
transmembrane growth factors proTGF-α and proAreg
fused to AP. Both EGF-like transmembrane growth fac-
tors are cleaved almost exclusively by ADAM17 in dif-
ferent cell types [18, 33], and the AP moiety allows
accurate quantitation of shedding [18]. As previously
shown [25–30], short-term treatment with MβCD acti-
vates ectodomain shedding (Additional file 8: Figure.
S3a); however, at longer time-points (48 h), MβCD had lit-
tle or no effect on the shedding of these factors in control
proliferating cells, whether they express p95HER2 or not
Fig. 3 Contribution of ADAM17 to the p95HER2-induced senescence secretome. a MCF7 Tet-Off p95HER2 cells constitutively expressing a control
shRNA (NT, non-targeting) or two independent shRNAs targeting ADAM17 (A17#1 and A17#2) were cultured with or without doxycycline for 7
days. Cells were then harvested and lysed, and cell lysates were analyzed by Western blotting with the indicated antibodies. b Senescence-
associated β-galactosidase was analyzed in the same cells as in (a). Representative bright-field images are shown. c The same cells as in (a) were
plated with or without doxycycline and counted at the indicated time points. The results represent averages of two independent determinations.
d The conditioned media of the same cells as in (a), treated without doxycycline, were analyzed by label-free quantitative proteomics in triplicate
(a-c). The heatmap shows log2FC of the normalized levels of soluble ectodomains. e-g The same cells as in (a) were treated with or without
doxycycline for 7 days. Conditioned media from the last two days and cell lysates were analyzed by enzyme-linked immunosorbent assay (e) or
Western blotting (f, g) as indicated. Quantification of at least three independent experiments is represented as average and standard deviation.
These results were reproduced by using the second stable cell line expressing an independent shRNA targeting ADAM17 (data not shown).
Doxy doxycycline
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esterol, MβCD induced a significant increase in the shed-
ding of both AP-tagged growth factors only in p95HER2-
induced senescent cells (Fig. 4c). The shedding of betacel-
lulin (BTC), a substrate of ADAM10 [18], was also un-
affected by the treatment with MβCD, ruling out
cholesterol as modulator of the activity of ADAM10 in
MCF7 cells (Fig. 4c).
We concluded that the increase in cholesterol content
in senescent cells downregulates the activity of ADAM17,
but not that of ADAM10, and results in accumulation of
partially inactive ADAM17. However, it should be under-
scored that the remaining ADAM17 activity is responsible
for the shedding of a variety of transmembrane molecules
during OIS (Fig. 3).Role of ADAM17 in non-cell autonomous effects of
p95HER2-induced senescence
To analyze the functional importance of ADAM17 activ-
ity during OIS, we compared the non-cell autonomous
effects of p95HER2-induced senescent cells with those
of the same cells knocked down for the metalloprotease
on different in vitro and in vivo assays.
Consistently with the production of Areg by senescent
cells, incubation of A431 cells, which overexpress the
EGFR, with the media conditioned by p95HER2-induced
senescent cells increased the levels of phospho-EFGR
(Additional file 8: Figure. S3b). Also, as expected, knock-
down of the metalloprotease completely inhibited the ef-
fect of the senescence secretome on phospho-EGFR
levels (Additional file 8: Figure. S3b).
Fig. 4 Effect of cholesterol depletion on the protein levels and activity of ADAM17 in p95HER2-induced senescent cells. a MCF7 Tet-Off p95HER2
cells were cultured with or without doxycycline for 5 days and further incubated in serum-free media with or without 1 mM MβCD for 2 additional
days. Then cells were stained with filipin. Representative bright-field and filipin staining images are shown. b The same cells as in (a) were treated with
different concentrations of MβCD. Control and treated cells were harvested and lysed, and cell lysates were analyzed by Western blot with the
indicated antibodies. The densitometric quantification of three independent experiments is expressed as average ± standard deviation. *P <0.05 using
the two-sided Student’s t test. c MCF7 Tet-Off p95HER2 or MCF10A Tet-On p95HER2 cells expressing AP-tagged TGF-α (left panels), Areg (middle panels),
or BTC (right panel) were treated with or without doxycycline and MβCD or vehicle for 48 h as indicated. AP was quantified in serum-free conditioned
media and cell lysates. Data shown represent the averages and standard deviations of three independent experiments. *P < 0.05 using the two-sided
Student’s t test. AP alkaline phosphatase, BTC betacellulin, Doxy doxycycline, MβCD methyl-beta-cyclodextrin, TGF transforming growth factor
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[34]. Accordingly, the secretome of p95HER2-induced
senescent cells promoted the migration of different
breast cancer cell lines (Fig. 5a). The knockdown of
ADAM17 with two independent shRNAs (Fig. 3a) abro-
gated the effect of the senescence secretome on cell mi-
gration (Fig. 5a and data not shown), indicating that
transmembrane factors cleaved by the metalloprotease
contribute to the pro-migratory effect of the senescence
secretome.
The secretome of p95HER2-induced senescent cells
promotes the metastatic growth of non-senescent cells
[2]. Because the migratory behavior of cells in vitro
(Fig. 5a) can be indicative of their metastatic potential
in vivo, we analyzed the effect on ADAM17 knockdown
on the non-cell autonomous prometastatic effect of
p95HER2-induced senescent cells. To this end, we co-
injected MCF7 Tet-Off p95HER2 cells with MDA-MB-231
cells expressing the luciferase reporter (MDA-MB-231
Luc cells) into nude mice and administered doxycycline in
the drinking water to initially prevent the expression ofp95HER2 from the MCF7 Tet-Off p95HER2 cells (Fig. 5b).
When the tumors, populated by both cell types, reached
approximately 100 mm3, doxycycline was removed from
the drinking water to allow the expression of p95HER2.
The knockdown of ADAM17 had little or no effect on the
growth of MDA-MB-231 cells in the primary tumor
(Fig. 5c, d). When the tumors reached approximately 300
mm3, we removed them and followed the fate of the
remaining MDA-MB-231 Luc cells. In the majority of the
cases, the primary tumors did not regrow; we only ob-
served growth of MDA-MB-231 Luc cells in the same lo-
cation of the primary tumors in two out of six mice from
the control group (data not shown). Thus, MDA-MB-231
Luc cells detected in the metastatic setting left the primary
tumor prior to its surgically resection. In a previous report
[2], we showed that p95HER2-induced senescent cells
promote the metastatic growth of MDA-MB-231 Luc
cells. Consistently, we detected metastasis in the axillary
ganglia and lungs of mice that had tumors composed of
p95HER2-induced senescent cells and MDA-MB-231 Luc
cells (Fig. 5e, f ). However, the knockdown of ADAM17
Fig. 5 Effect of ADAM17 knockdown on different non-cell autonomous effects of p95HER2-induced senescent cells. a Conditioned media from
MCF7 Tet-Off p95HER2 shNT or shADAM17 cells cultured in serum-free media for 48 h, after 5 days of plating with or without doxycycline (see
schematic drawing), were placed in the lower chamber of transwell plates; parental MCF7 or MDA-MB-231 cells were seeded on the upper chamber
(schematic drawing, upper panel). After 48 or 24 h, cells in the lower compartment were stained and fixed. Representative images with MDA-MB-231
cells are shown (middle panels). Migrating cells were estimated in three independent experiments (lower panels). Bars represent averages and standard
deviations. *P < 0.05, **P < 0.01, and ***P < 0.001 using the two-sided Student’s t test. b MCF7 Tet-Off p95HER2 cells constitutively expressing a control
shRNA (NT, non-targeting) or a shRNA targeting ADAM17 were co-injected orthothopically with reporter MDA-MB-231 cells expressing the luciferase
gene. c Tumor volumes were determined at the indicated time points and expressed as average ± standard deviation. Doxycycline was withdrawn at
the time indicated as 0. d Tumor growth determined by in vivo bioluminescence at day 16 (total photon flux emission). Results are expressed as
averages and standard deviations. e Representative in vivo bioluminescence images of metastatic sites 20 days after tumor resection. f Kaplan-Meier
plot showing metastasis-free survival of the same mice as in (c) and (d) after tumor resection.
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(Fig. 5e, f ), arguing that factors cleaved by ADAM17 pro-
mote the metastatic growth of MDA-MB-231 Luc cells.
The results presented here show the complex regula-
tion of ADAM17 during oncogene-induced senescence.
While cellular senescence results in the accumulation of
ADAM17 partially inhibited by cholesterol, the remaining
activity of the metalloprotease is functionally relevant. It
preferentially cleaves transmembrane molecules transcrip-
tionally upregulated during OIS and its activity is required
for some of the non-cell autonomous effects of senescentcells, including the promotion of cell migration and me-
tastasis. These results show that ADAM17 controls the
production of a subset of components of the senescence
secretome, which are functionally relevant during tumor
progression.
Discussion
In this work, we show that approximately one tenth of
the components of the senescence secretome are gener-
ated through protein ectodomain shedding (Additional
file 1: Figure. S1c) and that one third of these are cleaved
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the contribution of ADAM17-mediated ectodomain shed-
ding to the non-cell autonomous effects of oncogene-
induced senescent cells.
The regulation of ADAM17 during senescence is com-
plex. One of the intracellular pathways that activates
ADAM17 is the MEK-ERK pathway (reviewed in [35]).
Thus, one could assume that ADAM17 is activated in
p95HER2-induced senescent cells, where the ERK1,2
pathway is constitutively active [15] (Figs. 2a and 4b). In
fact, a recent report shows that ADAM17 is activated in
Ras-induced senescent cells [14]. However, our results
clearly show that activation of p95HER2 does not result
in ADAM17 activation. In fact, p95HER2-induced senes-
cent cells accumulate partially inactive ADAM17. This
restriction of ADAM17 activity is likely due to the accu-
mulation of cholesterol in senescent cells. This result
contrasts with that published by Effenberger et al., who
showed similar levels of ADAM17 in PC3 proliferating
cells and in the same cells after induction of senescence
with doxorubicin [14]. The likely explanation(s) for these
apparently disparate observation may reside in differ-
ences in the cell type (PC3 and MCF7 are derived from
prostate and breast cancers, respectively) or in the trigger
of senescence (DNA-damage induced by Doxorubicin ver-
sus expression of p95HER2) or in both. For instance,
ADAM17 levels and activity were differentially regulated
in MCF7 and MCF10, which are both of breast origin and
express the same oncogene.
Although the exact mechanism of ADAM17 inhibition
is not known, it seems to be related to the compartmen-
talization of the metalloproteinase in plasma membrane
subdomains where shedding substrates are not access-
ible [25–30]. In addition to increasing the activity of
ADAM17, MβCD decreased the levels of the metallo-
protease, particularly those of the processed form
(Fig. 4b). A way to interpret this result is by assuming
that ADAM17 inhibited by cholesterol has a longer half-
life than active ADAM17. Future work will be directed
to clarify whether these interpretations of the results ex-
plain not only the upregulation of the levels of ADAM17
and the restriction of its activity in p95HER2-induced
senescent cells but the differences observed between
p95HER2- and Ras-induced senescent cells as well.
The clear correlation between the levels of the tran-
scripts encoding shedding substrates and the levels of
ectodomains in the senescence secretome (Fig. 1d) indi-
cates that the activity of ADAM17 is limiting in senes-
cent cells: only substrates whose expression increases,
such as Met or Areg, are cleaved. Under these limiting
conditions, substrates whose expression does not in-
crease during senescence, such as APP, are probably out-
competed and, as a result, their shedding decreases
during OIS.Despite this restriction, the remaining activity of
ADAM17 clearly contributes to the protumorigenic ef-
fects of p95HER2-induced senescent cells. The data in
Fig. 5a show that factors whose secretion depends on
ADAM17 increase cell motility. This result, along with
the fact that the effect of ADAM17 is non-cell autono-
mous (Fig. 5c-f ), led us to conclude that the proteolytic
activity of ADAM17 acts on factors that, when released,
increase the metastatic ability of cancer cells.
Given the lack of modulators of the senescence secre-
tome and the fact that the activity of ADAM17 can be
upregulated by different compounds or inhibited with
small-molecule synthetic inhibitors (reviewed in [36]) or
monoclonal antibodies [37], our results open up a possi-
bility that part of the effects of the senescence secretome
can be modulated by regulating the activity of ADAM17.
Thus, the pharmacological modulation of ADAM17 may
represent a means to target the non-cell autonomous ef-
fects of cellular senescence, which may contribute to dif-
ferent diseases, including cancer [1].
Conclusions
p95HER2, an oncogenic fragment of the tyrosine kinase
receptor HER2, has been shown to induce senescence in
a variety of breast cancer cell lines, whereas its associ-
ated secretome promotes metastasis in a non-cell au-
tonomous manner. Analysis of this secretome showed
that several soluble factors are released through ectodo-
main shedding, but its specific contribution has not been
studied thoroughly. The present study shows that ap-
proximately 10 % of the p95HER2-induced secretome
components are generated by ectodomain shedding and
that the levels of shedding substrates are controlled also
transcriptionally. We identified ADAM17 as the main
sheddase involved in the generation of p95HER2-induced
secretome. ADAM17 activity, though, is restrained by the
accumulation of cellular cholesterol in senescent cells.
However, the remaining activity of ADAM17 is essential
to regulate the secretome composition and its functional
effect. In this sense, the secretome of p95HER2-induced
senescent cells that are knocked down for ADAM17 im-
pairs migration of proliferating cells both in vivo and
in vitro. Taken together, our results point out the import-
ance of ADAM17 in the regulation of p95HER2-induced
senescent secretome and its non-cell autonomous prome-
tastatic effects.
Additional files
Additional file 1: Figure. S1. Proteomic analysis of the secretome of
p95HER2-induced senescence. a MCF7 Tet-Off p95HER2 cells were
cultured with or without doxycycline for 1 week and stained for
senescence-associated β-galactosidase. Representative images of the
stained cultures are shown. b The secretomes of the same cells as in a
Morancho et al. Breast Cancer Research  (2015) 17:106 Page 12 of 13were analyzed by label-free quantitative proteomics. The results are
shown as unsupervised hierarchical clustering analysis corresponding to
three technical replicas (a-c) of two independent experiments (1 and 2).
c The proteins identified in b were classified according to the presence of
transmembrane or glycophosphatidylinositol domains (cell membrane),
signal peptide but not transmembrane domain (secreted, canonical), or the
lack of these domains (secreted, unknown). See also Additional file 2:
Table S1. Doxy doxycycline. (JPEG 585 kb)
Additional file 2: Table S1. Proteins identified by label-free quantitative
proteomics. Doxy doxycycline. (PDF 231 kb)
Additional file 3: Table S2. Proteins identified by label-free quantitative
proteomics secreted through the canonical pathway. Doxy doxycycline.
(PDF 44 kb)
Additional file 4: Table S3. Proteins identified by label-free quantitative
proteomics with transmembrane or GPI-anchored domains and mRNA levels
by transcriptomic analysis. Doxy doxycycline, GPI glycophosphatidylinositol.
(PDF 52 kb)
Additional file 5: Figure. S2. Alignment of peptides identified by label-
free quantitative proteomics on the primary sequence of the correspond-
ing transmembrane proteins. From Additional file 2: Table S1, we chose
the type I transmembrane proteins with the largest intracellular domains
and aligned the peptides identified through label-free quantitative prote-
omics to their primary sequence. The amino- and carboxy terminus of
the proteins are marked with N and C, respectively, the signal sequence
and the transmembrane domains are represented by red boxes, and pep-
tides identified by mass spectrometry are represented by yellow boxes.
The numbers on top of the schematics represent amino acid positions. In
each case, the number of amino acids corresponding to the peptides
identified by mass spectrometry and the number of amino acids of the
extracellular and intracellular domains, as well as the percentages, are
shown. (JPEG 265 kb)
Additional file 6: Table S4. List of confirmed proteins from label-free
proteomic analysis. (PDF 36 kb)
Additional file 7: Table S5. Proteins identified by label-free quantitative
proteomics in MCF7 Tet-Off p95HER2 shNT and shADAM17. Doxy
doxycycline, GPI glycophosphatidylinositol. (PDF 44 kb)
Additional file 8: Figure. S3. a Short-term cholesterol depletion
activates the shedding of AP-tagged TGF-α and Areg. MCF7 cells
expressing AP-tagged TGF-α or Areg were cultured with or without
doxycycline and treated with MβCD or vehicle for 1 h as indicated.
AP was quantified in serum-free conditioned media and cell lysates.
Data shown represent the averages and standard deviations of three
independent experiments. **P < 0.01 using the two-sided Student’s
t test. b The secretome of p95HER2-induced senescent cells contains
factors that activate the EGFR. A431 cells were stimulated with
conditioned media obtained from culturing MCF7 Tet-Off p95HER2
cells shNT or shADAM17 in serum-free media for 48 h, after 5 days
of plating with or without doxycycline (see schematic drawing).
Then A431 cell lysates were analyzed by Western blot by using the
indicated antibodies. Quantification of densitometric data is shown.
AP alkaline phosphatase, Areg amphiregulin, Doxy doxycycline, MβCD
methyl-beta-cyclodextrin, TGF-α transforming growth factor-alpha.
(JPEG 275 kb)Abbreviations
AP: Alkaline phosphatase; AP-Areg: Alkaline phosphatase-tagged
amphiregulin; AP-BTC: Alkaline phosphatase-tagged betacellulin;
APP: Amyloid precursor protein; AP-TGF-α: Alkaline phosphatase-tagged
transforming growth factor-alpha; Areg: Amphiregulin; EGF: Epidermal
growth factor; EGFR: Epidermal growth factor receptor; FBS: Fetal bovine
serum; MβCD: Methyl-beta-cyclodextrin; OIS: Oncogene-induced senescence;
PBS: Phosphate-buffered saline.Competing interests
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